These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 19825800

  • 1. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [Abstract] [Full Text] [Related]

  • 2. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
    Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF.
    Proc Natl Acad Sci U S A; 2001 Jun 19; 98(13):7443-8. PubMed ID: 11416216
    [Abstract] [Full Text] [Related]

  • 3. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.
    Cancer Res; 2000 Jan 15; 60(2):342-9. PubMed ID: 10667586
    [Abstract] [Full Text] [Related]

  • 4. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R.
    Cancer Res; 2006 Feb 01; 66(3):1721-9. PubMed ID: 16452232
    [Abstract] [Full Text] [Related]

  • 5. Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion.
    Kwak IH, Shin YH, Kim M, Cha HY, Nam HJ, Lee BS, Chaudhary SC, Pai KS, Lee JH.
    Exp Mol Med; 2011 Feb 28; 43(2):111-20. PubMed ID: 21209554
    [Abstract] [Full Text] [Related]

  • 6. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q.
    J Transl Med; 2018 Sep 12; 16(1):253. PubMed ID: 30208970
    [Abstract] [Full Text] [Related]

  • 7. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.
    Jeffers M, Rong S, Vande Woude GF.
    Mol Cell Biol; 1996 Mar 12; 16(3):1115-25. PubMed ID: 8622656
    [Abstract] [Full Text] [Related]

  • 8. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
    Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF.
    Oncogene; 2005 May 26; 24(23):3697-707. PubMed ID: 15782129
    [Abstract] [Full Text] [Related]

  • 9. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
    Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE.
    Cancer Res; 2010 Jan 15; 70(2):639-45. PubMed ID: 20068147
    [Abstract] [Full Text] [Related]

  • 10. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
    Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J.
    J Natl Cancer Inst; 1999 Sep 15; 91(18):1548-56. PubMed ID: 10491431
    [Abstract] [Full Text] [Related]

  • 11. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
    Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wacheck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J.
    Clin Cancer Res; 2014 Dec 01; 20(23):6059-70. PubMed ID: 25231402
    [Abstract] [Full Text] [Related]

  • 12. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
    Moriyama T, Kataoka H, Koono M, Wakisaka S.
    Int J Mol Med; 1999 May 01; 3(5):531-6. PubMed ID: 10202187
    [Abstract] [Full Text] [Related]

  • 13. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z.
    Biochem Biophys Res Commun; 2015 Aug 14; 464(1):154-60. PubMed ID: 26093299
    [Abstract] [Full Text] [Related]

  • 14. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
    Dai Y, Siemann DW.
    BMC Cancer; 2012 May 28; 12():198. PubMed ID: 22639908
    [Abstract] [Full Text] [Related]

  • 15. Met-HGF/SF: tumorigenesis, invasion and metastasis.
    Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J.
    Ciba Found Symp; 1997 May 28; 212():119-30; discussion 130-2, 148-54. PubMed ID: 9524767
    [Abstract] [Full Text] [Related]

  • 16. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
    Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E.
    J Biol Chem; 1999 Jun 04; 274(23):16377-86. PubMed ID: 10347197
    [Abstract] [Full Text] [Related]

  • 17. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R.
    Cancer Res; 2005 Oct 15; 65(20):9355-62. PubMed ID: 16230398
    [Abstract] [Full Text] [Related]

  • 18. Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor.
    Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, Vande Woude GF, Gross MD.
    Mol Imaging; 2002 Oct 15; 1(1):56-62. PubMed ID: 12920861
    [Abstract] [Full Text] [Related]

  • 19. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
    Jeffers M, Rong S, Anver M, Vande Woude GF.
    Oncogene; 1996 Aug 15; 13(4):853-6. PubMed ID: 8761307
    [Abstract] [Full Text] [Related]

  • 20. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I, Ayalon-Soffer M.
    Clin Cancer Res; 2008 Jul 15; 14(14):4612-21. PubMed ID: 18628476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.